SignalFDA/Bio
Shanghai Junshi Biosciences (SEHK:1877) Reaches Three Phase 3 Cancer Trial Milestones
Three Phase 3 cancer trial milestones reached by Shanghai Junshi Biosciences.
Context
What happened: Shanghai Junshi Biosciences (SEHK:1877) reported first patient dosing in a phase 3 trial of JS207/JS007 for advanced hepatocellular carcinoma and began dosing in a separate phase 3 study of JS203 in relapsed or refractory diffuse large B cell lymphoma.
Why it matters: The company said the trials remain in the investment phase, so pipeline strength does not yet answer how durable eventual oncology revenues could be. Material impact depends on phase 3 readouts and regulatory traction.
What changed
Shanghai Junshi Biosciences (SEHK:1877) reported first patient dosing in a phase 3 trial of JS207/JS007 for advanced hepatocellular carcinoma and began dosing in a separate phase 3 study of JS203 in relapsed or refractory diffuse large B cell lymphoma.
Why it matters
The company said the trials remain in the investment phase, so pipeline strength does not yet answer how durable eventual oncology revenues could be. Material impact depends on phase 3 readouts and regulatory traction.